139 related articles for article (PubMed ID: 2900538)
1. Blockade of hippocampal dopamine (DA) receptors: a tool for antipsychotics with low extrapyramidal side effects.
Bischoff S; Christen P; Vassout A
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(4):455-67. PubMed ID: 2900538
[TBL] [Abstract][Full Text] [Related]
2. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.
Ogren SO; Hall H; Köhler C; Magnusson O; Sjöstrand SE
Psychopharmacology (Berl); 1986; 90(3):287-94. PubMed ID: 2947255
[TBL] [Abstract][Full Text] [Related]
3. Studies on the mechanism of action of substituted benzamide drugs.
Köhler C; Ogren SO; Fuxe K
Acta Psychiatr Scand Suppl; 1984; 311():125-37. PubMed ID: 6142588
[TBL] [Abstract][Full Text] [Related]
4. Prolonged inhibition of striatal dopamine receptor sites by isofloxythepin.
Lau YS; Runice C
Eur J Pharmacol; 1985 Oct; 116(1-2):25-31. PubMed ID: 2865162
[TBL] [Abstract][Full Text] [Related]
5. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
[TBL] [Abstract][Full Text] [Related]
6. Effects of calcitonin on rat extrapyramidal motor system: behavioral and biochemical data.
Nicoletti F; Clementi G; Patti F; Canonico PL; Di Giorgio RM; Matera M; Pennisi G; Angelucci L; Scapagnini U
Brain Res; 1982 Nov; 250(2):381-5. PubMed ID: 6293644
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems.
Van Ree JM; Elands J; Király I; Wolterink G
Eur J Pharmacol; 1989 Aug; 166(3):441-52. PubMed ID: 2572429
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl)benzocycloalkanones as analogues of butyrophenone.
Fontenla JA; Osuna J; Rosa E; Castro ME; G-Ferreiro T; Loza-García I; Calleja JM; Sanz F; Rodríguez J; Raviña E
J Med Chem; 1994 Aug; 37(16):2564-73. PubMed ID: 7914540
[TBL] [Abstract][Full Text] [Related]
9. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Ogren SO; Hall H; Köhler C; Magnusson O; Lindbom LO; Angeby K; Florvall L
Eur J Pharmacol; 1984 Jul; 102(3-4):459-74. PubMed ID: 6149133
[TBL] [Abstract][Full Text] [Related]
10. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
11. Effect of buflomedil (4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxy phenyl)-1-butanone hydrochloride) on the function of striatal dopaminergic neurons.
Koda H; Hashimoto T; Kuriyama K
Jpn J Pharmacol; 1989 Feb; 49(2):215-23. PubMed ID: 2659861
[TBL] [Abstract][Full Text] [Related]
12. Neuropharmacological and behavioural properties of remoxipride in the rat.
Ogren SO; Florvall L; Hall H; Magnusson O; Angeby-Möller K
Acta Psychiatr Scand Suppl; 1990; 358():21-6. PubMed ID: 1978483
[TBL] [Abstract][Full Text] [Related]
13. Involvement of different dopamine receptors in rat diphasic motility response to apomorphine.
Vaccheri A; Dall'Olio R; Gandolfi O; Montanaro N
Psychopharmacology (Berl); 1986; 89(3):265-8. PubMed ID: 2873607
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D-2 antagonists reverse apomorphine-induced decreased water intake in the rat: prediction of antipsychotic drugs with few extrapyramidal side-effects?
Ljungberg T
J Neural Transm; 1989; 76(2):79-90. PubMed ID: 2565360
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic activity of substituted gamma-carbolines.
Abou-Gharbia M; Patel UR; Webb MB; Moyer JA; Andree TH; Muth EA
J Med Chem; 1987 Oct; 30(10):1818-23. PubMed ID: 2888898
[TBL] [Abstract][Full Text] [Related]
16. 3-Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds.
Saller CF; Salama AI
Naunyn Schmiedebergs Arch Pharmacol; 1986 Oct; 334(2):125-32. PubMed ID: 2878374
[TBL] [Abstract][Full Text] [Related]
17. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
[TBL] [Abstract][Full Text] [Related]
18. "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics.
Stahl SM
J Clin Psychiatry; 2001 Sep; 62(9):670-1. PubMed ID: 11681760
[TBL] [Abstract][Full Text] [Related]
19. CI-943, a potential antipsychotic agent. II. Neurochemical effects.
Pugsley TA; Coughenour LL; Myers SL; Shih YH; Courtland GG; Berghoff W; Stewart SF
J Pharmacol Exp Ther; 1989 Oct; 251(1):113-22. PubMed ID: 2571713
[TBL] [Abstract][Full Text] [Related]
20. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.
Iorio LC; Barnett A; Leitz FH; Houser VP; Korduba CA
J Pharmacol Exp Ther; 1983 Aug; 226(2):462-8. PubMed ID: 6135795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
